Please login to the form below
Data by
25
Revenue 2014Merck KGaA
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.
Pfizer could raise ‘up to $15bn’ from consumer unit sale
Pfizer is also not alone in its tinkering, and consumer health assets have been changing hands with some frequency in recent years, with Merck KGaA saying last month it is also ... 2015 asset-swap deal, and Bayer bought Merck &Co's consumer unit for
Merck earmarks €35m for Italian biologics site development
Merck earmarks 35m for Italian biologics site development. Pharma firm plans new biotech production line at its Bari facility. ... Merck KgAa is set to invest 35m to expand its manufacturing site in the town of Modugno, Bari in Italy, to add a new
Finalists 2017
by Merck KGaA. with support from W2O Group. Talking About Diabetes (TAD) 2016. ... Merck Growth Hormone eHealth Programme. by Merck KGaA. with support from W2O Group.
Deal Watch May 2017
This ratio sounds familiar (see Becton Dickinson above). The second deal Fresenius announced this month is the acquisition of the biosimilar business of Merck KGaA, set up in 2012, for $729m ... 852 (800m) (533 upfront). Merck KGaA (DE) biosimilars.
Merck, Pfizer cue up first EU launch for PD-L1 drug Bavencio
Merck KGaA and Pfizer's PD-L1 inhibitor Bavencio could be on the EU market from next month, after getting EMA approval as a treatment for the rare skin cancer Merkel ... The new product will be launched first in the UK and Germany, according to Merck,
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| CNS revenue 2014 |
|---|
| 1: Pfizer |
| 2: Biogen Idec |
| 3: Novartis |
| 4: Otsuka |
| 5: Teva |
| 6: Johnson & Johnson |
| 7: Lilly |
| 8: Merck KGaA |
| 9: AstraZeneca |
| 10: Shire |
| 11: Bristol-Myers Squibb |
| 12: UCB |
| 13: Lundbeck |
| 14: Eisai |
| 15: GlaxoSmithKline |
| 16: Sanofi |
| 17: Mylan |
| 18: Indivior |
| 19: Actavis |
| 20: Bayer |
| Metabolic revenue 2014 |
|---|
| 1: Novo Nordisk |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Lilly |
| 5: AstraZeneca |
| 6: Takeda |
| 7: Novartis |
| 8: Amgen |
| 9: Bayer |
| 10: Merck KGaA |
| 11: Salix Pharmaceuticals |
| 12: AbbVie |
| 13: Dainippon Sumitomo Pharma |
| 14: Kyowa Hakko Kirin |
| 15: Mitsubishi Tanabe |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Scientific Director, Medical Communications
-
£60 – 70, 000 benefits
-
Account Director at PAREXEL MedCom
-
Competitive Salary
- Account Director, Healthcare Communications
-
£50, 000 - £60, 000
-
Editorial Director - BioScience
-
Competitive Salary
-
Account Director
-
Salary TBC
-
Medical Editor
-
Great salary and benefits
- Digital Account Director – Healthcare Communications
-
£50 – 60, 000 benefits
-
Principal Medical Writer
-
Great salary and benefits
- Scientific Team Leader, Medical Education
-
£55, 000 – £70, 000 benefits
Subscribe to our email news alerts
PMHub
PharmiWeb Solutions
PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...
Latest intelligence
- Tools for the digital world
- The next step for the pharma industry...
- How Can We Make Payer Communications Really Sing?
- With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
- Harnessing the power of core elements to optimise market access
- This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
Quick links
Infographics
